Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity bumps up target price on Harbour Energy

(Sharecast News) - Analysts at Canaccord Genuity nudged up their target price on independent oil and gas company Harbour Energy from 275p to 285p on Friday after the group released "a very strong set" of H1 numbers. Canaccord Genuity said Harbour's H1 results pointed to strong production levels, reduced operating costs, "excellent" free cash flow generation, and an "impressive" reduction in net debt.

The Canadian bank also noted that Harbour announced a $100m share buyback for 2025, in addition to the approximately $455m of dividends guided to, for a total of roughly $550m of shareholder returns for 2025.

"Given the uncertainties some have had over the upside potential of the Harbour/Wintershall DEA combination, we believe the progress made in H1 should put most to rest with the Harbour team proving its operational prowess over multiple jurisdictions," said Canaccord Genuity.

"In our view, the area of most interest is the FCF performance and net debt reduction achieved in the first half. Thanks to better-than-expected production, timely hedging and improved cost management, the free cash has really driven the material reduction in net debt. While we do expect a slight reversion here in H2, this is our first real sign of what the combined businesses can do."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.